Literature DB >> 6725947

Treatment of experimental visceral leishmaniasis with lymphokine encapsulated in liposomes.

S G Reed, M Barral-Netto, J A Inverso.   

Abstract

Highly susceptible mice were infected with Leishmania donovani chagasi and were treated with supernatants, free or encapsulated in liposomes, from concanavalin A-stimulated or unstimulated mouse spleen cell cultures. Treatment consisted of multiple i.v. injections beginning 2 days before to 2 days after infection. Mice treated with lymphokine-rich supernatants encapsulated in liposomes had significantly fewer liver parasites than the control groups, demonstrating in vivo activity of lymphokine against an infectious organism.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6725947

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

Review 1.  Liposomes as drug delivery system in the treatment of infectious diseases. Potential applications and clinical experience.

Authors:  A Coune
Journal:  Infection       Date:  1988 May-Jun       Impact factor: 3.553

2.  Interferon gamma encapsulated into liposomes enhances the activity of monocytes and natural killer cells and has antiproliferative effects on tumor cells in vitro.

Authors:  I Rutenfranz; A Bauer; H Kirchner
Journal:  Blut       Date:  1990-07

3.  Enhanced efficacy of liposome-encapsulated ribavirin against Rift Valley fever virus infection in mice.

Authors:  M Kende; C R Alving; W L Rill; G M Swartz; P G Canonico
Journal:  Antimicrob Agents Chemother       Date:  1985-06       Impact factor: 5.191

4.  Treatment of experimental salmonellosis in mice with streptomycin entrapped in liposomes.

Authors:  T Tadakuma; N Ikewaki; T Yasuda; M Tsutsumi; S Saito; K Saito
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

5.  Interleukin 10 production correlates with pathology in human Leishmania donovani infections.

Authors:  H W Ghalib; M R Piuvezam; Y A Skeiky; M Siddig; F A Hashim; A M el-Hassan; D M Russo; S G Reed
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

6.  Interferon-gamma in starch microparticles: nitric oxide-generating activity in vitro and antileishmanial effect in mice.

Authors:  L Degling; P Stjärnkvist; I Sjöholm
Journal:  Pharm Res       Date:  1993-06       Impact factor: 4.200

7.  Pathophysiology of experimental leishmaniasis: pattern of development of metastatic disease in the susceptible host.

Authors:  J O Hill
Journal:  Infect Immun       Date:  1986-05       Impact factor: 3.441

8.  Protective immunization with a novel membrane protein of Plasmodium yoelii-infected erythrocytes.

Authors:  J M Burns; E K Adeeku; P D Dunn
Journal:  Infect Immun       Date:  1999-02       Impact factor: 3.441

Review 9.  Cytokines: Key Determinants of Resistance or Disease Progression in Visceral Leishmaniasis: Opportunities for Novel Diagnostics and Immunotherapy.

Authors:  Alti Dayakar; Sambamurthy Chandrasekaran; Suresh V Kuchipudi; Suresh K Kalangi
Journal:  Front Immunol       Date:  2019-04-05       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.